Tada Group AB Successfully Closes Investment Round in Challenging Market of 2022. Raising capital in today's market can be a difficult and challenging task, but it is also an invaluable learning experience.
Having a revolutionary innovation that can reshape the future of IV therapy and coming out to the market at the right time is nothing short of amazing. The insane potential of ReLink as well as new IPR has contributed to our fresh start of 2023. My co-founders Rebecca Bejhed and Christopher Blacker, the rest of the team, our investors and I are looking forward to this new year.